Berlin

• APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participant … Ended recruitment
  2024-520407-27-00 5 2025-10-23 X-Linked Protoporphyria (XLP)
• A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended recruitment
  2024-519469-23-00 4 2025-10-20 Severe Asthma
• Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended recruitment
  2025-521681-10-00 4 2025-10-02 Lung Cancer
• A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended recruitment
  2024-518811-20-00 4 2025-09-30 Early-Stage, PIK3CA-Mutated Breast Cancer (BC)
• Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended recruitment
  2025-520488-42-00 4 2025-09-17 Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
• Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria Ended recruitment
  2024-520031-33-00 4 2025-09-16 Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
• A Study to Find Out How Safe and Effective AZD0780 Is for Adults with High 'Bad' Cholesterol from an Inherited Condition Ended recruitment
  2025-520520-17-00 5 2025-09-05 Heterozygous familial hypercholesterolaemia
• A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended recruitment
  2025-520521-21-00 5 2025-09-02 Hyperlipidemia
• A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended recruitment
  2024-518457-42-00 4 2025-08-28 chronic kidney disease
• A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Gen … Ended recruitment
  2024-513572-17-00 5 2025-08-20 Generalized Anxiety Disorder (GAD)
• A clinical study of tulisokibart in people with hidradenitis suppurativa (MK-7240-012) Ended recruitment
  2024-520039-33-00 10 2025-08-11 Hidradenitis Suppurativa
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended recruitment
  2024-517356-35-00 4 2025-07-29 Moderately Active Rheumatoid Arthritis
• Rezafungin for treatment of chronic pulmonary aspergillosis (CPA) in adults with limited treatment options Ended recruitment
  2024-519575-26-00 4 2025-07-25 Chronic pulmonary aspergillosis (CPA)
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• A Trial of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) Ended recruitment
  2024-519095-66-00 5 2025-07-23 Kidney Transplant Recipients with Late Antibody-Mediated Rejection
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended recruitment
  2024-517143-31-00 4 2025-07-18 Autosomal Dominant Polycystic Kidney Disease
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening); … Ended recruitment
  2024-519000-27-00 5 2025-07-17 Hypertension
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended recruitment
  2022-503001-38-01 5 2025-07-08 HR-positive HER-2- negative Breast Cancer
• A Safety, and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED) Ended recruitment
  2024-519417-57-00 5 2025-06-25 Thyroid eye disease
• Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended recruitment
  2024-517817-34-00 9 2025-06-18 Gastric Cancer
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended recruitment
  2024-516051-40-00 4 2025-06-10 Small Cell Lung Cancer (SCLC)

Showing 865–888 of 1,776 trials